Navigation Links
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Date:8/17/2010

INDIANAPOLIS, Aug. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

The company's decision does not affect the ongoing clinical trials of solanezumab, Lilly's other compound in Phase III trials as a potential Alzheimer's treatment. While both drugs focus on amyloid-beta proteins, which are believed to play a critical role in Alzheimer's disease, they have different mechanisms of action. Lilly also has two other compounds in earlier stages of clinical development; those studies are not affected by today's announcement.

In two pivotal Phase III trials, semagacestat was compared with placebo in more than 2,600 patients with mild-to-moderate Alzheimer's disease. Lilly has now reviewed data from a pre-planned interim analysis of semagacestat studies. This interim analysis showed that, as expected, cognition and the ability to complete activities of daily living of placebo-treated patients worsened.  However, by these same measures, patients treated with semagacestat worsened to a statistically significantly greater degree than those treated with placebo. In addition, data showed semagacestat is associated with an increased risk of skin cancer compared with those who received placebo.

"This is disappointing news for the millions of Alzheimer's patients and their families worldwide who anxiously await a successful treatment for this devastating illness," said Jan M. Lundberg, Ph.D., Executive Vice President, Science and Technology, and President, Lilly Research Laboratories. "This is a se
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, ... being named a “Best of the Best” firm in the U.S., as well as ... “Best of the Best” in the U.S., selected exclusively on performance in specific areas ...
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... that, to date, more than 1,500 investor-families have received permanent green cards (I-829 ... EB-5 projects. , The I-829 petition is the final step of the EB-5 ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence ... of products, the VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions ... Calm, and Clear. , Formulated with alpha hydroxy acids and natural active ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... new patients directly from Practice Perfect to FOTO enabling cost and time savings, ... , Steven Presement, President of Practice Perfect, stated "FOTO is a natural ...
(Date:9/1/2015)... ... , ... A new episode of “Voices In America”, hosted by famous actor ... of arthritis. There are over 100 different types of arthritis. One of the most ... an effort to shed light on this important topic. , Anyone who is nearing ...
Breaking Medicine News(10 mins):Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:FOTO Announces New Integration Partnership with Practice Perfect 2
... LYON, France, October 15 Sanofi Pasteur, ... a partnership,with Institut Pasteur to develop a ... Pasteur will have access to antigens,identified by ... responsible for the most deadly malaria infections. ...
... Colo. (October 15, 2007) Patients have on average ... nations top-rated hospitals compared with the lowest-rated hospitals across ... HealthGrades Hospital Quality in America Study, issued today by ... a wide variation in the quality of care between ...
... likely contributor to the way that some folks eat to ... University at Buffalo, The State University of New York, have ... helps make behaviors and substances more rewarding, find food to ... they are more motivated to eat and they eat more. ...
... to advance understanding of ills such as heart disease ... of the largest collections of genetic and clinical data ... the U.S. National Institutes of Health. , The Web-based ... to access data from a number of large population-based ...
... in Support of National Breast ... Cure, DALLAS, Oct. 13 NASCAR drivers Bobby ... Cure at today,s Bank of,America 500 race at Lowe,s ... ) Bobby Labonte,s #43, sponsored by General Mills, ...
... Garcia, Huffman), the California Routine HIV Screening,Bill, ... Foundation, the,California Medical Association, & the Health ... & Reduce HIV Transmission, SACRAMENTO, Calif., ... operator of the largest non-government HIV testing,program ...
Cached Medicine News:Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 3Health News:Genes may make some people more motivated to eat, perhaps overeat 2Health News:Genes may make some people more motivated to eat, perhaps overeat 3Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:General Mills' #43, M&M's #38 Driving Passionately Pink for the Cure at Lowe's Motor Speedway NASCAR Race 2Health News:Schwarzenegger Signs Bill to Remove Written Informed Consent for HIV Testing; "Most Important Change in Public HIV/AIDS Policy in Years," Says AHF 2Health News:Schwarzenegger Signs Bill to Remove Written Informed Consent for HIV Testing; "Most Important Change in Public HIV/AIDS Policy in Years," Says AHF 3Health News:Schwarzenegger Signs Bill to Remove Written Informed Consent for HIV Testing; "Most Important Change in Public HIV/AIDS Policy in Years," Says AHF 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: